

HIV

References

1. *The Relationship Between the Human Immunodeficiency Virus and the Acquired Immunodeficiency Syndrome*. Bethesda, MD: National Institute of Allergy and Infectious Diseases; 1995. Available at: www.niaid.nih.gov/Publications/hivaids/hivaids.htm. Accessed January 19, 2006.
2. *The Evidence that HIV Causes AIDS*. Bethesda, MD: National Institute of Allergy and Infectious Diseases; 2003. Available at: www.niaid.nih.gov/Factsheets/evidhiv.htm. Accessed January 19, 2006.
3. *HIV and AIDS in Canada: Surveillance Report to December 31, 2004*. Ottawa, ON: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; 2005. Available at: www.phac-aspc.gc.ca/publicat/aids-sida/haic-vsac1204/index.html. Accessed January 19, 2006.
4. *HIV/AIDS — Epi Updates — 2005*. Ottawa, ON: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; 2005. Available at: www.phac-aspc.gc.ca/publicat/epiu-aepi/epi-05/index.html. Accessed January 19, 2006.
5. *Understanding the HIV/AIDS Epidemic among Aboriginal Peoples in Canada: The Community at a Glance. HIV/AIDS Epi Notes*. December 2004. Ottawa, ON: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; 2004. Available at: www.phac-aspc.gc.ca/publicat/epiu-aepi/epi-note/index.html. Accessed January 19, 2006.
6. *HIV/AIDS and Hepatitis C in Prisons: The Facts*. Montreal, QC: Canadian HIV/AIDS Legal Network; 2004. Available at: www.aidslaw.ca/Maincontent/issues/prisons/e-revinfo-pa1.pdf. Accessed January 19, 2006.
7. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. *Lancet* 1989;2:403–407.
8. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med* 2000;342:921–929.
9. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. *J Infect Dis* 2005;191:1403–1409.
10. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? *Sex Transm Dis* 2001;28:579–597.
11. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect* 1999;75:3–17.
12. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. *Nat Rev Microbiol* 2004;2:33–42.
13. Mabey D. Interactions between HIV infection and other sexually transmitted diseases. *Trop Med Int Health* 2000;5:A32–36.

14. Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. *JAMA* 1988;260:1429–1433.
15. Hook EW 3rd, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. *J Infect Dis* 1992;165:251–255.
16. Guenther PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. *Infect Immun* 2005;73:4155–4160.
17. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. *J Infect Dis* 1994;170:1597–1601.
18. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. *Lancet* 1997;350:546–550.
19. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. *J Infect Dis* 1999;180:1863–1868.
20. Cu-Uvin S, Hogan JW, Caliendo AM, et al. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. *Clin Infect Dis* 2001;33:894–896.
21. Sha BE, Zariffard MR, Wang QJ, et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. *J Infect Dis* 2005;191:25–32.
22. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected persons starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360:119–129.
23. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men in San Francisco. *Am J Public Health* 2002;92:388–394.
24. Chen SY, Gibson S, Katz MH, et al. Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, California, 1999–2001, USA. *Am J Public Health* 2002;92:1387–1388.
25. Wolitski RJ, Valdiserri RO, Denning PH, Levine WC. Are we headed for a resurgence of the HIV epidemic among men who have sex with men? *Am J Public Health* 2001;91:883–888.
26. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. *AIDS* 2000;14:117–121.
27. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. *Lancet* 1997;349:1868–1873.
28. Centers for Disease Control and Prevention. HIV prevention through early detection and treatment of other sexually transmitted diseases — United States. Recommendations of the Advisory Committee for HIV and STD Prevention. *MMWR Recomm Rep* 1998;47(RR-12):1–24.

29. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. *J Infect Dis* 2001;183:1017–1022.
30. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. *AIDS* 2001;15:105–110.
31. Harwell JI, Flanigan TP, Mitty JA, et al. Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence. *AIDS* 2003;17:1990–1993.
32. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. *MMWR Recomm Rep* 2001;50(RR-19):1–57.
33. Horsburgh CR Jr, Ou CY, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. *Lancet* 1989;2:637–640.
34. Busch MP, Lee LL, Satten GA, et al. Time course of detection viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. *Transfusion* 1995;35:91–97.
35. *After Cuerrier: Canadian Criminal Law and the Non-Disclosure of HIV-Positive Status*. Montreal, QC: Canadian HIV/AIDS Legal Network; 1999. Available at: www.aidslaw.ca/Maincontent/issues/criminallaw/finalreports/cuerrier/tofc.htm. Accessed January 19, 2006.
36. Elliott R, Betteridge G. HIV-positive person who did not disclose status convicted of attempted aggravated assault. *Can HIV Aids Policy Law Rev* 2003;8:50–53
37. Persons who fail to disclose their HIV/AIDS status: conclusions reached by an expert working group. *Can Commun Dis Rep* 2005;31:53–61.
38. Lee TH, Sakahara N, Fiebig E, Busch MP, O'Brien TR, Herman SA. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;12:427–428.
39. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. *N Engl J Med* 1997;336:1072–1078.
40. *HIV Transmission: Guidelines for Assessing Risk. A Resource for Educators, Counsellors, and Health Care Providers*. 5th ed. Ottawa, ON: Canadian AIDS Society; 2004.
41. Centers for Disease Control and Prevention (CDC). Update: barrier protection against HIV infection and other sexually transmitted diseases. *MMWR Morb Mortal Wkly Rep* 1993;42:589–591, 597.
42. *Fact Sheet for Public Health Personnel 2002: Male Latex Condoms and Sexually Transmitted Diseases*. Atlanta, GA: Centers for Disease Control and Prevention; 2002. Available at: www.cdcnpin.org/FactSheets/condom.pdf. Accessed January 19, 2006.
43. Carey RF, Herman WA, Retta SM, Rinaldi JE, Herman BA, Athey TW. Effectiveness of latex condoms as a barrier to human immunodeficiency virus-sized particles under conditions of simulated use. *Sex Transm Dis* 1992;19:230–234.
44. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. *Sex Transm Inf* 2005;81:193–200.

45. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV screening of pregnant women. *MMWR Recomm Rep* 2001;50(RR-19):63–85.
46. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; US Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. *MMWR Recomm Rep* 2005;54(RR-9):1–17.
47. Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. *Am J Med* 1997;102(5B):9–15.
48. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV Infection. *Arch Int Med* 1993;153:1451–1458.
49. Centers for Disease Control (CDC). Update: human immunodeficiency virus infections in health-care workers exposed to blood of infected patients. *MMWR Morb Mortal Wkly Rep* 1987;36:285–289.
50. Fahey BJ, Koziol DE, Banks SM, Henderson DK. Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. *Am J Med* 1991;90:145–153.
51. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. *Ann Intern Med* 1990;113:740–746.
52. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. *N Engl J Med* 1997;337:1485–1490.
53. Mast ST, Woolwine JD, Gerberding JL. Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury. *J Infect Dis* 1993;168:1589–1592.
54. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. *Arch Intern Med* 1988;148:945–949.
55. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. *Ann Intern Med* 1996;125:257–264.
56. Quinn TC. Acute primary HIV infection. *JAMA* 1997;278:58–62.
57. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. *N Engl J Med* 1998;339:33–39.
58. Pilcher CD, Tien HC, Eron JJ Jr, et al; Quest Study; Duke-UNC-Emory Acute HIV Consortium. Brief but efficient: acute HIV infection and the sexual transmission of HIV. *J Infect Dis* 2004;189:1785–1792.
59. Moylett EH, Shearer WT. HIV: clinical manifestations. *J Allergy Clin Immunol* 2002;110:3–16.
60. Health and Welfare Canada. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. *CDWR* 1987;13-38:169–177.
61. Revision of the surveillance case definition for AIDS in Canada. *CCDR* 1993;19-15:116–117.
62. Branson BM. Point-of-care rapid tests for HIV antibody. *J Lab Med* 2003;27:288–295.

63. Aberg JA, Gallant JE, Anderson J, et al; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis* 2004;39:609–629.
64. Hecht FM, Wilson IB, Wu AW, Cook RL, Turner BJ. Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. *Ann Intern Med* 1999;131:136–143.
65. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med* 1997;126:946–954.
66. Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. *AIDS* 2004;18:2419–2423.
67. Long R, Houston S, Hershfield E; Canadian Tuberculosis Committee of the Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada. Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. *CMAJ* 2003;169:789–791.
68. Hoepfner V, Marciniuk D, Hershfield E. Treatment of tuberculosis disease and infection. In: Long R, ed. *Canadian Tuberculosis Standards*. 5th ed. Ottawa, ON: Canadian Lung Association and Health Canada; 2000: 83–109.
69. *Canadian Immunization Guide*. 6th ed. Ottawa, ON: Health Canada; 2002.
70. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule — United States, October 2005–September 2006. Available at: www.cdc.gov/nip/recs/adult-schedule.htm. Accessed January 19, 2006.
71. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. *Ann Intern Med* 2003;138:453–459.
72. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. *Sex Transm Dis* 2004;31:96–99.
73. *Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents*. Rockville, MD: AIDSinfo, Department of Health and Human Services; 2005. Available at: aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 19, 2006.
74. Kaplan JE, Masur H, Holmes KK; USPHS; Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Disease Society of America. *MMWR Recomm Rep* 2002;51(RR-8):1–52.
75. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. *J Infect Dis* 2002;185:45–52.
76. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. *J Infect Dis* 2003;187:1513–1521.
77. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2

- infection: a nested case-control study in Rakai, Uganda. *J Infect Dis* 2003;188:1492–1497.
78. Renzi C, Douglas JM Jr, Foster M, et al. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. *J Infect Dis* 2003;187:19–25.
 79. Celum CL. The interaction between herpes simplex virus and human immunodeficiency virus. *Herpes* 2004;11(suppl 1):36A–45A.
 80. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. *JAMA* 1998;280:61–66.
 81. Golden MP, Kim S, Hammer SM, et al. Activation of human immunodeficiency virus by herpes simplex virus. *J Infect Dis* 1992;166:494–499.
 82. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. *J Infect Dis* 1997;176:766–770.
 83. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. *J Infect Dis* 2002;186:1718–1725.
 84. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. *Lancet* 2000;355:1981–1987.
 85. Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. *J Infect Dis* 2005;191(suppl 1):S107–S114.
 86. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. *Am J Obstet Gynecol* 1991;164:593–599.
 87. Duerr A, Kieke B, Warren D, et al; HER study group. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. *Am J Obstet Gynecol* 2001;184:584–590.
 88. Smith DK, Grohskopf LA, Black RJ, et al; U.S. Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. *MMWR Recomm Rep* 2005;54(RR-2):1–20.
 89. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis* 2001;33:562–569.
 90. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. *J Infect Dis* 2001;183:1112–1155.
 91. Puoti M, Airoidi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. *AIDS Rev* 2002;4:27–35.

92. Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. *Clin Infect Dis* 2004;38:1471–1417.
93. Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections. *J HIV Ther* 2003;8:77–84.
94. Johns DR, Tierney M, Felsenstein D. Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus. *N Engl J Med* 1987;316:1569–1572.
95. Hutchinson CM, Hook EW 3rd, Shepherd M, Verley J, Rompalo AM. Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. *Ann Intern Med* 1994;121:94–100.
96. Gordon SM, Eaton ME, George R, et al. The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection. *N Engl J Med* 1994;331:1469–1473.
97. Malone JL, Wallace MR, Hendrick BB, et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent serologic relapse after therapy. *Am J Med* 1995;99:55–63.